Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision

The failure of another trial adds to uncertainty around the effectiveness of Duchenne gene therapy, though analysts don’t believe it’ll affect the FDA’s decision to widen use of Sarepta’s Elevidys.